(R)-(-)-苯乙基内酰脲结构式
|
常用名 | (R)-(-)-苯乙基内酰脲 | 英文名 | (R)-(-)-N-[1-(1-NAPHTHYL)ETHYL]-3,5-DINITROBENZAMIDE |
|---|---|---|---|---|
| CAS号 | 65567-32-0 | 分子量 | 204.22500 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C11H12N2O2 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07 |
信号词 | Warning |
| 中文名 | (R)-(-)-苯乙基内酰脲 |
|---|---|
| 英文名 | (5R)-5-ethyl-5-phenylimidazolidine-2,4-dione |
| 中文别名 | 5-乙基-5-苯基海因 |
| 分子式 | C11H12N2O2 |
|---|---|
| 分子量 | 204.22500 |
| 精确质量 | 204.09000 |
| PSA | 58.20000 |
| LogP | 1.78890 |
| InChIKey | UDTWZFJEMMUFLC-LLVKDONJSA-N |
| SMILES | CCC1(c2ccccc2)NC(=O)NC1=O |
| 符号 |
GHS07 |
|---|---|
| 信号词 | Warning |
| 危害声明 | H302-H315-H319-H335 |
| 警示性声明 | P261-P305 + P351 + P338 |
| 个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
| 危害码 (欧洲) | Xn |
| 风险声明 (欧洲) | 22-36/37/38 |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 2 |
| RTECS号 | MU2452000 |
| 海关编码 | 2933990090 |
| (R)-(-)-苯乙基内酰脲上游产品 0 | |
|---|---|
| (R)-(-)-苯乙基内酰脲下游产品 1 | |
| 海关编码 | 2933990090 |
|---|---|
| 中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes.
Chem. Res. Toxicol. 6(2) , 188-96, (1993) The pharmacodynamics of rat hepatic cytochrome P450 2B (P450 2B) induction by phenobarbital (PB) and two structural congeners, dl-5-ethyl-5-phenylhydantoin (EPH) and dl-5-ethyl-5-phenyloxazolidinedion... |
|
|
A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats.
Biochem. Pharmacol. 43(5) , 1079-87, (1992) Phenobarbital (PB) and certain structurally-related compounds induce a variety of hepatic drug-metabolizing enzymes in many strains of rats. Thus, following administration of PB (300, 500 ppm), barbit... |
|
|
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
Arch. Biochem. Biophys. 429(1) , 1-15, (2004) Three series of N-3 alkyl substituted phenytoin, nirvanol, and barbiturate derivatives were synthesized and their inhibitor potencies were tested against recombinant CYP2C19 and CYP2C9 to probe the in... |